ObsEva commences Phase III trials of OBE2109 to treat uterine fibroids
Swiss-based biopharmaceutical firm ObsEva has commenced its Phase III clinical trial programme of OBE2109 to treat uterine fibroids (UF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Pharmaceuticals